Recommended Premedication for IRRs

The following premedications are recommended before beginning the GAZYVA (obinutuzumab) infusion to reduce the risk of IRRs 1

Premedication and close monitoring are recommended for all patients 1

  • Patients with preexisting cardiac or pulmonary conditions are at a greater risk of experiencing more severe infusion reactions
  • Hypotension may occur during GAZYVA intravenous infusions. Consider withholding antihypertensive treatments for 12 hours prior to and throughout each GAZYVA infusion and for the first hour after administration
  • Patients with high tumor burden, high circulating absolute lymphocyte counts (greater than 25 x 109/L), or renal impairment are considered at risk of tumor lysis syndrome and should receive prophylaxis. Premedicate with antihyperuricemics (eg, allopurinol or rasburicase) and ensure adequate hydration prior to start of GAZYVA therapy. Continue prophylaxis prior to each subsequent GAZYVA infusion, as needed
  • Patients with Grade 3 to 4 neutropenia lasting more than one week are strongly recommended to receive antimicrobial prophylaxis until resolution of neutropenia to Grade 1 or 2. Antiviral and antifungal prophylaxis should be considered